Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HIV gp120 vaccine - VaxGen

Next Previous
Drug Profile

HIV gp120 vaccine - VaxGen

Alternative Names: AIDSVAX; AIDSVAX B/B'; AIDSVAX B/E; HIV gp120 vaccine - Genentech; HIV gp120 vaccine AIDSVAX - VaxGen; HIV vaccine AIDSVAX - VaxGen; rgp120/HIV-1MN

Latest Information Update: 04 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech; VaxGen
  • Developer Centre Hospitalier Universitaire Vaudois; EuroVacc Foundation; Genentech; Global Solutions for Infectious Diseases; International AIDS Vaccine Initiative; MRC/UVRI Uganda Research Unit on AIDS; VaxGen
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II HIV-1 infections

Most Recent Events

  • 31 Dec 2024 MRC/UVRI Uganda Research Unit completes a phase-II clinical trials in HIV infections (Combination therapy, Prevention) in Uganda (IM) (NCT04066881)
  • 28 Aug 2022 No recent reports of development identified for phase-I development in HIV-1-infections(In neonates, Prevention) in Puerto Rico (IM, Injection)
  • 28 Aug 2022 No recent reports of development identified for phase-I development in HIV-1-infections(In neonates, Prevention) in USA (IM, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top